FDA's Process Validation Guidance Stresses Use of Statistical Controls
This article was originally published in The Gold Sheet
FDA's process validation guidance puts a new emphasis on statistical controls. Like it or not, the guidance offers new flexibility. Also, it expands the focus of process validation from commercial scale-up to a lifecycle approach that includes process design studies as well as continuous verification during commercial manufacturing activities.
You may also be interested in...
Overcoming Fear of ‘CPV Monster,’ Drug Makers Launch Continued Process Verification Programs
Most pharmaceutical manufacturers are adopting or making plans to adopt the continued process verification approach outlined in FDA’s November 2011 process validation guidance, which will shine a light on their manufacturing processes. But not everyone is anxious to see what that light will reveal.
Top Stories of 2014
Readers of “The Gold Sheet” focused more on articles about data integrity than any other topic last year, which is a big reason why data integrity was the No. 1 story of 2014. A number of other highly read articles last year focused on additional topics that were also among the top stories in pharmaceutical manufacturing quality last year.
FDA Removes Tracking Of Operator Errors From Process Validation Guidance
PhRMA and Pfizer successfully lobbied to have the recommendation taken out of the final guidance, calling it "too prescriptive."